Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

The US Court of Appeals for the Federal Circuit affirmed a district court’s delisting of patents from the Orange Book because the patent claims ...

On December 20, 2024, the US Court of Appeals for the Federal Circuit released its opinion in Teva Branded Pharm. Prods. R&D, Inc. v. Amneal ...

Health insurance rules capping monthly out-of-pocket costs for insulin, asthma inhalers, and epinephrine injectors took effect on New Year’s Day. The provisions, required under a law Gov. Phil Murphy ...

Inhaled corticosteroids all share properties that make them effective topical antiinflammatory agents for treatment of asthma with minimal adverse systemic effects, particularly when administered ...

Leak Rate. It is common for MDIs to lose propellant during storage. The propellant-leak rate of the test MDIs was compared with that of the controls (Figure 3). The leak rates for the Proventil ...

Amneal beats Teva’s challenge of ruling on some ProAir patents Decision could impact other ‘junk device listings,’ FTC says Five patents related to Teva Pharmaceutical Industries Ltd.’s ProAir HFA ...

ProAir HFA inhaler from the Food and Drug Administration’s Orange Book. Amneal plans to market a generic version of the inhaler and had argued that Teva’s patents were incorrectly included on ...